A GTM + GCC-penetration plan to win engineering & regulatory work inside India-based MedTech / pharma / life-sciences Global Capability Centers (GCCs). Load it into the platform to see every workspace populated, or take the whole thing as a download bundle.
NovintiX wins by being the MedTech-native specialist pod a large GCC can turn on in weeks — landing on one scoped device family, proving audit-ready output, then expanding.
The buyers already have global SIs on an MSA and regulatory boutiques on a call list. What they are short of is specialist engineering bandwidth that builds the evidence — design-history files, UDI/EUDAMED records, SaMD V&V — for one device family, fast, under an existing vendor framework.
That gap is exactly NovintiX's footprint: device product engineering + regulatory/quality + clinical & data engineering, delivered as one accountable scope. The GTM job is to make that footprint legible to the right six roles inside each GCC and to convert it into a repeatable land-and-expand motion.
Why GCCs, why now
India hosts the densest concentration of MedTech and life-sciences GCCs in the world — Medtronic's largest R&D center outside the US, plus engineering and digital-health centers for GE HealthCare, Siemens Healthineers, Philips, Boston Scientific, Stryker, BD, Baxter, Abbott, J&J MedTech and the diagnostics majors.
These centers are moving up the value chain from support to owning device programs, SaMD and regulatory evidence. That shift creates a structural, recurring shortage of specialist design-control, UDI/EUDAMED and SaMD-V&V capacity — the exact work NovintiX productizes.
Regulatory pressure (EU MDR/IVDR, EUDAMED go-live, FDA design-control and UDI enforcement, IEC 62304 for SaMD) turns that shortage into deadline-driven demand with a named owner — the ideal trigger for a scoped, fast micro-pilot.
Ideal customer profile (ICP)
Who: MedTech / diagnostics / life-sciences GCCs in India, 200–5,000 seats, with active device or SaMD programs — new setups (<2y) that lack specialist bench and scaling/mature centers whose bench is bandwidth-constrained.
Where: Bengaluru, Hyderabad, Pune, Chennai, NCR.
Trigger events: EUDAMED/UDI deadline, an audit finding, a device-family launch, a SaMD/AI feature entering review, a new site charter, or a senior reg/quality leader change.
Why they buy NovintiX over the alternatives: MedTech-native (no ramp tax), evidence-building not advisory, fixed-scope and fast, and able to slot under an existing MSA without a 12-month transformation program.
The buying center — six roles to cover
Deals die when only one role is mapped. The GCC workspace scores each account across all six; the target is ≥4 covered before a proposal.
Role
Who it is
How to win them
Economic Buyer
VP / Head of Device R&D or Engineering — owns the budget and the program P&L.
Frame the pod as capacity that protects the roadmap and de-risks a deadline.
Champion
Head of Regulatory Affairs & Quality — feels the UDI/submission pain first.
Give them a scoped win they can point to; make them look proactive to their exec.
Technical Evaluator
Principal/Staff V&V or design-control engineer.
Prove the evidence approach is credible with a sample artefact, not a pitch.
Procurement & Vendor Management
Owns MSA, rate card, security review.
Fit the existing vendor framework; make onboarding trivial.
Gatekeeper
Chief of Staff / EA to the site head.
Earn calendar access with a specific, relevant reason to meet.
End Users
Device program & project engineers.
Make the pod easy to work alongside; they become internal advocates.
The penetration motion — land small, prove, expand
LandEnter on ONE device family with a fixed-scope micro-pilot (UDI Sprint or a design-control/V&V slice). Small enough to buy under existing authority, real enough to prove audit-ready output.
ProveDeliver validated, audit-ready evidence at handoff. Capture a reference and a case study (see Philips worked example).
ExpandGrow the micro-pilot into a device-family engagement, then a standing engineering pod across families — moving from project to retained capacity.
RepeatUse each reference to shorten the next center's evaluation. The account book is tiered so effort concentrates on act-now accounts (advanced stage × coverage gap).
The productized offer ladder
Every service is a fixed-scope offer with a clear promise and price band — so buyers can say yes without a bespoke SOW.
Offer
Promise
Price · time
MedTech Engineering Health Check
Scored design-control & submission readiness + costed plan
$8k–$15k · ~1 week
UDI Sprint
GUDID/EUDAMED-ready UDI records for one device family, validated & audit-ready
$25k–$60k · 6 weeks
SaMD Assurance Pack
IEC 62304-aligned V&V evidence a notified body accepts
$40k–$90k · ~8 weeks
Design-Control Accelerator
Audit-ready DHF & ISO 14971 risk file for one device family
$60k–$120k · ~11 weeks
Bespoke Engineering Pod
Embedded device-engineering capacity, retained
$30k–$50k/mo
Positioning & messaging
Category: "MedTech-native product-engineering & regulatory pod for GCCs." Not an SI, not an advisory boutique.
Against global SIs: "We land in weeks on one device family and build the evidence — not a 12-month transformation staffed by generalists."
Against regulatory boutiques: "We build the DHF, the UDI records and the V&V evidence — not just the recommendations."
Against status quo (in-house): "We are the flex specialist pod that clears the backlog without adding headcount — under your existing vendor framework."
Proof spine: concept-to-commercialization under one accountable scope; MedTech/device/diagnostics/SaMD focus; a fixed-scope, audit-ready deliverable per engagement.
Channels & cadence
Primary: founder-led, peer-to-peer outreach to the economic buyer + champion (LinkedIn + email), sequenced with the platform's Win a GCC exec cadence and personalized with each account's WHY-NOW trigger.
Convener: small executive roundtables ("Design Controls & UDI in MedTech GCCs") to earn warm access to reg/quality leaders across several centers at once.
Referral: every delivered engagement produces a reference and a warm intro to a peer center — the highest-yield channel once the first logo lands.
Content: a small, sharp library — a UDI/EUDAMED readiness checklist, a design-control gap self-assessment, and one written case study — used as first-touch value, not volume marketing.
Funnel math & KPIs
Coverage: ≥4 of 6 buying-center roles mapped on every act-now account before a proposal.
Activity: 8–12 target accounts in active outreach; each with a dated cadence and a next-touch on the calendar.
Leading indicators: first meetings booked, micro-pilots scoped, references captured, roundtable acceptances. Lagging: revenue per device family, expansion rate, retained-pod count.
The plans — 30, 90, 180 days and 1 year
Each horizon has a theme, a single goal, concrete work items, and hard exit criteria. They chain: 30 days aims the motion, 90 lands the first pilot, 180 proves and expands, the year builds the repeatable engine.
30 days
Aim & first touches
Goal. Instrument the motion and open the first act-now accounts.
FoundationsLoad this worked example into the platform. Confirm the firm profile, ICP and offer ladder. Finalize the tiered account book (A0/A/B) from the 12 seeded GCCs + 30 more qualified from the 51-GCC landscape.
AssetsShip three first-touch assets: UDI/EUDAMED readiness checklist, design-control gap self-assessment, and the one-page NovintiX capability brief. Draft the Philips micro-pilot case study.
Buying-center mappingFor the top 6 act-now accounts, map ≥3 of 6 roles (economic buyer, champion, technical evaluator at minimum) using role placeholders → real names.
OutreachLaunch the Win a GCC exec cadence on the top 3 accounts (Medtronic MEIC, Boston Scientific, Stryker). Personalize each first touch with the account's WHY-NOW trigger.
ConvenerSet the date and invite list for the "Design Controls & UDI" executive roundtable (Bengaluru, ~Aug 21).
Exit criteria. 3 accounts in active cadence, top-6 accounts ≥3 roles mapped, 3 assets live, roundtable dated.
90 days
First meetings → first micro-pilot
Goal. Convert outreach into meetings and land the first paid micro-pilot.
Scale outreach8–12 accounts in active, dated cadences. Every act-now account at ≥4 of 6 buying-center roles covered before any proposal.
MeetingsBook 4–6 first meetings with economic buyers/champions. Use the account brief (coverage, why-now, next move) to prep each.
RoundtableRun the executive roundtable; convert 2–3 attendees into scoping conversations.
LandScope and close 1 UDI Sprint or Health Check micro-pilot on one device family. Fit it under an existing MSA where possible.
Proof loopDeliver the micro-pilot to audit-ready state; capture the reference and turn it into the first written case study.
Exit criteria. 4–6 first meetings, 1 micro-pilot sold and in delivery, 1 reference in progress, roundtable run.
180 days
Prove & expand
Goal. Turn the first win into an expansion and a repeatable second and third pilot.
Expand the first logoGrow the landed micro-pilot into a device-family engagement (e.g., Philips UDI Sprint → Design-Control Accelerator). Open the retained-pod conversation.
Second & third pilotsClose 2–3 more micro-pilots across the account book, using the first case study to shorten evaluation.
Pod readinessStandardize the two highest-repeat offers (UDI Sprint, Health Check) — templates, checklists, delivery playbook — so delivery scales without founder time.
Buying-center depthEvery active opportunity at ≥4 roles; procurement and technical-evaluator engaged early to avoid late-stage stalls.
Pipeline hygienePortfolio review weekly — act-now first (advanced stage × coverage gap). Disqualify and re-aim stalled accounts.
Exit criteria. 1 expansion in motion, 3–4 total pilots delivered/closed, 2 offers productized, 2+ references.
1 year
From founder-led deals to a repeatable engine
Goal. Establish NovintiX as a known specialist pod across a cluster of MedTech GCCs, with a retained engagement and a referral flywheel.
Retained capacityConvert 1–2 expansions into standing engineering pods (monthly retained) — the base-load revenue.
Reference flywheel3–5 written case studies and reference customers; each new center's evaluation shortened by a peer proof point.
Offer portfolioFull ladder live and priced; SaMD Assurance Pack and Design-Control Accelerator each sold at least twice.
Coverage of the cluster40–50 GCC targets qualified; 12–15 first meetings cumulatively; presence established in Bengaluru + Hyderabad + Pune MedTech clusters.
Team & deliveryDelivery playbooks and templates let associate engineers run standardized offers; founder time shifts to expansion and new-logo landing.
Adjacent expansionTest one adjacent segment from the landscape (diagnostics/IVDR or pharma manufacturing-quality) with a single scoped pilot.
One click seeds the full NovintiX example across all seven workspaces so you can click through the real motion — the account book, the buying-center coverage, the campaign cadence, the productized offer, the capability maps and the plans.
Before it writes anything, the loader downloads a backup of your current platform data (so nothing is lost), then merges the NovintiX example in. You can also do this manually: Settings → Restore full backup with the downloaded novintix-platform-seed.json.
This is a directional GTM research aid built on public information about NovintiX and the India GCC landscape. Target company names are real and used illustratively to show the motion — verify every account, contact and trigger independently before any outreach. Contacts in the worked example are ROLE placeholders, not real individuals. NovintiX is not affiliated with any named company, and no named company has endorsed this plan.